nodes	percent_of_prediction	percent_of_DWPC	metapath
Celecoxib—Sulfaphenazole—Dapsone—leprosy	0.505	1	CrCrCtD
Celecoxib—PTGS2—Thalidomide—leprosy	0.109	0.324	CbGbCtD
Celecoxib—PTGS2—Dapsone—leprosy	0.0874	0.259	CbGbCtD
Celecoxib—CYP2C9—Thalidomide—leprosy	0.0372	0.11	CbGbCtD
Celecoxib—CYP2C9—Rifampicin—leprosy	0.036	0.107	CbGbCtD
Celecoxib—CYP2C9—Dapsone—leprosy	0.0297	0.0879	CbGbCtD
Celecoxib—CYP3A4—Rifampicin—leprosy	0.0209	0.062	CbGbCtD
Celecoxib—CYP3A4—Dapsone—leprosy	0.0173	0.0511	CbGbCtD
Celecoxib—CA6—ear—leprosy	0.00516	0.176	CbGeAlD
Celecoxib—Nephrotic syndrome—Dapsone—leprosy	0.00267	0.0289	CcSEcCtD
Celecoxib—MAPK14—blood vessel—leprosy	0.00226	0.0771	CbGeAlD
Celecoxib—Albuminuria—Dapsone—leprosy	0.00173	0.0187	CcSEcCtD
Celecoxib—Intestinal perforation—Thalidomide—leprosy	0.00167	0.0181	CcSEcCtD
Celecoxib—Proteinuria—Dapsone—leprosy	0.00147	0.0159	CcSEcCtD
Celecoxib—Protein urine present—Dapsone—leprosy	0.00145	0.0157	CcSEcCtD
Celecoxib—Neck stiffness—Thalidomide—leprosy	0.00139	0.015	CcSEcCtD
Celecoxib—PTGS2—hindlimb—leprosy	0.00136	0.0464	CbGeAlD
Celecoxib—CA4—nerve—leprosy	0.00135	0.0461	CbGeAlD
Celecoxib—Sinus bradycardia—Thalidomide—leprosy	0.00135	0.0146	CcSEcCtD
Celecoxib—Transient ischaemic attack—Thalidomide—leprosy	0.00131	0.0142	CcSEcCtD
Celecoxib—Nuchal rigidity—Thalidomide—leprosy	0.00127	0.0138	CcSEcCtD
Celecoxib—Skin exfoliation—Dapsone—leprosy	0.00123	0.0134	CcSEcCtD
Celecoxib—PDPK1—testis—leprosy	0.00123	0.042	CbGeAlD
Celecoxib—PDPK1—nervous system—leprosy	0.00121	0.0413	CbGeAlD
Celecoxib—PTGS2—appendage—leprosy	0.00117	0.0398	CbGeAlD
Celecoxib—Deep vein thrombosis—Thalidomide—leprosy	0.00109	0.0118	CcSEcCtD
Celecoxib—MAPK14—skin of body—leprosy	0.00104	0.0357	CbGeAlD
Celecoxib—Nail disorder—Thalidomide—leprosy	0.00102	0.011	CcSEcCtD
Celecoxib—Tooth disorder—Thalidomide—leprosy	0.00102	0.011	CcSEcCtD
Celecoxib—MAPK14—activated TAK1 mediates p38 MAPK activation—RIPK2—leprosy	0.000997	0.0278	CbGpPWpGaD
Celecoxib—Intestinal obstruction—Thalidomide—leprosy	0.00097	0.0105	CcSEcCtD
Celecoxib—Menstrual disorder—Thalidomide—leprosy	0.00097	0.0105	CcSEcCtD
Celecoxib—PTGS2—skin epidermis—leprosy	0.000969	0.0331	CbGeAlD
Celecoxib—MAPK14—NOD1/2 Signaling Pathway—CYLD—leprosy	0.000957	0.0267	CbGpPWpGaD
Celecoxib—Neuralgia—Thalidomide—leprosy	0.000952	0.0103	CcSEcCtD
Celecoxib—PDPK1—Downstream TCR signaling—RIPK2—leprosy	0.000949	0.0265	CbGpPWpGaD
Celecoxib—CA12—eye—leprosy	0.00091	0.0311	CbGeAlD
Celecoxib—MAPK14—activated TAK1 mediates p38 MAPK activation—NOD2—leprosy	0.000904	0.0252	CbGpPWpGaD
Celecoxib—Albuminuria—Thalidomide—leprosy	0.000886	0.00959	CcSEcCtD
Celecoxib—Cholestasis—Thalidomide—leprosy	0.000871	0.00943	CcSEcCtD
Celecoxib—MAPK14—Senescence and Autophagy in Cancer—TNFSF15—leprosy	0.000868	0.0242	CbGpPWpGaD
Celecoxib—Nasopharyngitis—Dapsone—leprosy	0.000839	0.00908	CcSEcCtD
Celecoxib—CA9—tendon—leprosy	0.000815	0.0279	CbGeAlD
Celecoxib—MAPK14—tendon—leprosy	0.000795	0.0272	CbGeAlD
Celecoxib—Pancreatitis—Dapsone—leprosy	0.000795	0.0086	CcSEcCtD
Celecoxib—MAPK14—IL4-mediated signaling events—LTA—leprosy	0.00078	0.0218	CbGpPWpGaD
Celecoxib—CA14—tendon—leprosy	0.000773	0.0264	CbGeAlD
Celecoxib—Proteinuria—Thalidomide—leprosy	0.000753	0.00815	CcSEcCtD
Celecoxib—Protein urine present—Thalidomide—leprosy	0.000742	0.00804	CcSEcCtD
Celecoxib—Photosensitivity reaction—Dapsone—leprosy	0.00074	0.00801	CcSEcCtD
Celecoxib—Musculoskeletal stiffness—Thalidomide—leprosy	0.000737	0.00798	CcSEcCtD
Celecoxib—Viral infection—Thalidomide—leprosy	0.000732	0.00793	CcSEcCtD
Celecoxib—Bone disorder—Thalidomide—leprosy	0.000732	0.00793	CcSEcCtD
Celecoxib—Arthropathy—Thalidomide—leprosy	0.000727	0.00787	CcSEcCtD
Celecoxib—Cellulitis—Thalidomide—leprosy	0.000727	0.00787	CcSEcCtD
Celecoxib—MAPK14—Parkinsons Disease Pathway—PARK2—leprosy	0.000719	0.0201	CbGpPWpGaD
Celecoxib—Herpes simplex—Thalidomide—leprosy	0.000718	0.00777	CcSEcCtD
Celecoxib—Drug interaction—Thalidomide—leprosy	0.000713	0.00772	CcSEcCtD
Celecoxib—PDPK1—TCR signaling—RIPK2—leprosy	0.000709	0.0198	CbGpPWpGaD
Celecoxib—Neuropathy peripheral—Dapsone—leprosy	0.000708	0.00767	CcSEcCtD
Celecoxib—Hypercholesterolaemia—Thalidomide—leprosy	0.000699	0.00757	CcSEcCtD
Celecoxib—Creatinine increased—Thalidomide—leprosy	0.000695	0.00752	CcSEcCtD
Celecoxib—Hearing impaired—Thalidomide—leprosy	0.000695	0.00752	CcSEcCtD
Celecoxib—Sinusitis—Dapsone—leprosy	0.000678	0.00734	CcSEcCtD
Celecoxib—CA9—testis—leprosy	0.000675	0.0231	CbGeAlD
Celecoxib—Blood uric acid increased—Thalidomide—leprosy	0.000673	0.00729	CcSEcCtD
Celecoxib—Pulmonary embolism—Thalidomide—leprosy	0.000661	0.00716	CcSEcCtD
Celecoxib—Phosphatase alkaline increased—Thalidomide—leprosy	0.000661	0.00716	CcSEcCtD
Celecoxib—MAPK14—testis—leprosy	0.000658	0.0225	CbGeAlD
Celecoxib—MAPK14—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—CYLD—leprosy	0.000653	0.0182	CbGpPWpGaD
Celecoxib—Eructation—Thalidomide—leprosy	0.00065	0.00704	CcSEcCtD
Celecoxib—PTGS2—blood vessel—leprosy	0.000649	0.0222	CbGeAlD
Celecoxib—MAPK14—nervous system—leprosy	0.000646	0.0221	CbGeAlD
Celecoxib—Pharyngitis—Dapsone—leprosy	0.000644	0.00697	CcSEcCtD
Celecoxib—Colitis—Thalidomide—leprosy	0.000635	0.00688	CcSEcCtD
Celecoxib—Candida infection—Thalidomide—leprosy	0.000631	0.00684	CcSEcCtD
Celecoxib—Skin exfoliation—Thalidomide—leprosy	0.000631	0.00684	CcSEcCtD
Celecoxib—Blood urea increased—Thalidomide—leprosy	0.000624	0.00676	CcSEcCtD
Celecoxib—Neuropathy—Thalidomide—leprosy	0.000621	0.00672	CcSEcCtD
Celecoxib—Aplastic anaemia—Thalidomide—leprosy	0.000621	0.00672	CcSEcCtD
Celecoxib—MAPK14—NOD1/2 Signaling Pathway—RIPK2—leprosy	0.000617	0.0172	CbGpPWpGaD
Celecoxib—Cramps of lower extremities—Thalidomide—leprosy	0.000608	0.00658	CcSEcCtD
Celecoxib—Tinnitus—Dapsone—leprosy	0.000605	0.00655	CcSEcCtD
Celecoxib—Oesophagitis—Thalidomide—leprosy	0.000604	0.00654	CcSEcCtD
Celecoxib—Rash maculo-papular—Thalidomide—leprosy	0.000601	0.00651	CcSEcCtD
Celecoxib—PDPK1—TCR signaling in naïve CD8+ T cells—CD8A—leprosy	0.000586	0.0163	CbGpPWpGaD
Celecoxib—PDPK1—Downstream TCR signaling—HLA-DRB1—leprosy	0.000585	0.0163	CbGpPWpGaD
Celecoxib—Hypertonia—Thalidomide—leprosy	0.00058	0.00628	CcSEcCtD
Celecoxib—Sepsis—Thalidomide—leprosy	0.000574	0.00621	CcSEcCtD
Celecoxib—MAPK14—NOD1/2 Signaling Pathway—NOD2—leprosy	0.000559	0.0156	CbGpPWpGaD
Celecoxib—Thrombophlebitis—Thalidomide—leprosy	0.000555	0.006	CcSEcCtD
Celecoxib—Blood alkaline phosphatase increased—Thalidomide—leprosy	0.000552	0.00598	CcSEcCtD
Celecoxib—Diabetes mellitus—Thalidomide—leprosy	0.000552	0.00598	CcSEcCtD
Celecoxib—Photosensitivity—Thalidomide—leprosy	0.000547	0.00592	CcSEcCtD
Celecoxib—Gastroenteritis—Thalidomide—leprosy	0.000542	0.00586	CcSEcCtD
Celecoxib—CA5B—tendon—leprosy	0.000541	0.0185	CbGeAlD
Celecoxib—Deafness—Thalidomide—leprosy	0.000537	0.00581	CcSEcCtD
Celecoxib—Vision blurred—Dapsone—leprosy	0.000532	0.00576	CcSEcCtD
Celecoxib—Eye pain—Thalidomide—leprosy	0.000532	0.00576	CcSEcCtD
Celecoxib—Cardiac failure congestive—Thalidomide—leprosy	0.000529	0.00573	CcSEcCtD
Celecoxib—Renal failure acute—Thalidomide—leprosy	0.00052	0.00563	CcSEcCtD
Celecoxib—Increased appetite—Thalidomide—leprosy	0.000511	0.00553	CcSEcCtD
Celecoxib—Dermatitis exfoliative—Thalidomide—leprosy	0.000509	0.00551	CcSEcCtD
Celecoxib—Vertigo—Dapsone—leprosy	0.000507	0.00549	CcSEcCtD
Celecoxib—PDPK1—TCR Signaling Pathway—RIPK2—leprosy	0.000506	0.0141	CbGpPWpGaD
Celecoxib—Dermatitis bullous—Thalidomide—leprosy	0.000502	0.00544	CcSEcCtD
Celecoxib—Cough—Dapsone—leprosy	0.000493	0.00534	CcSEcCtD
Celecoxib—Hypoglycaemia—Thalidomide—leprosy	0.000492	0.00533	CcSEcCtD
Celecoxib—Cardiac failure—Thalidomide—leprosy	0.000492	0.00533	CcSEcCtD
Celecoxib—CA12—nervous system—leprosy	0.00049	0.0167	CbGeAlD
Celecoxib—Cerebrovascular accident—Thalidomide—leprosy	0.00049	0.0053	CcSEcCtD
Celecoxib—Hyponatraemia—Thalidomide—leprosy	0.000482	0.00522	CcSEcCtD
Celecoxib—Gastrointestinal haemorrhage—Thalidomide—leprosy	0.00048	0.0052	CcSEcCtD
Celecoxib—Osteoarthritis—Thalidomide—leprosy	0.00048	0.0052	CcSEcCtD
Celecoxib—Migraine—Thalidomide—leprosy	0.000473	0.00512	CcSEcCtD
Celecoxib—CA2—eye—leprosy	0.000467	0.016	CbGeAlD
Celecoxib—MAPK14—Toll-like Receptor Signaling Pathway—TLR1—leprosy	0.000467	0.013	CbGpPWpGaD
Celecoxib—Face oedema—Thalidomide—leprosy	0.000463	0.00502	CcSEcCtD
Celecoxib—Ataxia—Thalidomide—leprosy	0.000451	0.00489	CcSEcCtD
Celecoxib—Tachycardia—Dapsone—leprosy	0.00045	0.00487	CcSEcCtD
Celecoxib—Blood creatinine increased—Thalidomide—leprosy	0.00045	0.00487	CcSEcCtD
Celecoxib—CA5B—testis—leprosy	0.000448	0.0153	CbGeAlD
Celecoxib—Liver function test abnormal—Thalidomide—leprosy	0.000443	0.0048	CcSEcCtD
Celecoxib—Dry skin—Thalidomide—leprosy	0.00044	0.00476	CcSEcCtD
Celecoxib—CA5B—nervous system—leprosy	0.00044	0.015	CbGeAlD
Celecoxib—PDPK1—TCR signaling—HLA-DRB1—leprosy	0.000438	0.0122	CbGpPWpGaD
Celecoxib—Hypokalaemia—Thalidomide—leprosy	0.000437	0.00473	CcSEcCtD
Celecoxib—Breast disorder—Thalidomide—leprosy	0.000434	0.0047	CcSEcCtD
Celecoxib—Aspartate aminotransferase increased—Thalidomide—leprosy	0.000432	0.00468	CcSEcCtD
Celecoxib—Toxic epidermal necrolysis—Thalidomide—leprosy	0.000432	0.00468	CcSEcCtD
Celecoxib—Alanine aminotransferase increased—Thalidomide—leprosy	0.000423	0.00458	CcSEcCtD
Celecoxib—MAPK14—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—RIPK2—leprosy	0.000421	0.0117	CbGpPWpGaD
Celecoxib—MAPK14—CD40/CD40L signaling—CD40LG—leprosy	0.000419	0.0117	CbGpPWpGaD
Celecoxib—Insomnia—Dapsone—leprosy	0.000417	0.00451	CcSEcCtD
Celecoxib—Dysphagia—Thalidomide—leprosy	0.000415	0.00449	CcSEcCtD
Celecoxib—PDPK1—Downstream TCR signaling—CD4—leprosy	0.000413	0.0115	CbGpPWpGaD
Celecoxib—Eosinophilia—Thalidomide—leprosy	0.000411	0.00445	CcSEcCtD
Celecoxib—Bronchospasm—Thalidomide—leprosy	0.000408	0.00442	CcSEcCtD
Celecoxib—Pancreatitis—Thalidomide—leprosy	0.000407	0.0044	CcSEcCtD
Celecoxib—CA2—skin of body—leprosy	0.000407	0.0139	CbGeAlD
Celecoxib—ABCC4—tendon—leprosy	0.000406	0.0139	CbGeAlD
Celecoxib—Angina pectoris—Thalidomide—leprosy	0.000404	0.00438	CcSEcCtD
Celecoxib—PDPK1—TCR signaling in naïve CD4+ T cells—HLA-DRB1—leprosy	0.0004	0.0112	CbGpPWpGaD
Celecoxib—Bronchitis—Thalidomide—leprosy	0.000399	0.00432	CcSEcCtD
Celecoxib—Pancytopenia—Thalidomide—leprosy	0.000394	0.00427	CcSEcCtD
Celecoxib—PDPK1—Costimulation by the CD28 family—HLA-DRB1—leprosy	0.000391	0.0109	CbGpPWpGaD
Celecoxib—ORM1—nervous system—leprosy	0.000389	0.0133	CbGeAlD
Celecoxib—Upper respiratory tract infection—Thalidomide—leprosy	0.000386	0.00418	CcSEcCtD
Celecoxib—MAPK14—MAP kinase activation in TLR cascade—RIPK2—leprosy	0.000384	0.0107	CbGpPWpGaD
Celecoxib—PDPK1—TCR Signaling Pathway—CD8A—leprosy	0.000383	0.0107	CbGpPWpGaD
Celecoxib—Pollakiuria—Thalidomide—leprosy	0.000383	0.00415	CcSEcCtD
Celecoxib—MAPK14—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—NOD2—leprosy	0.000381	0.0106	CbGpPWpGaD
Celecoxib—Photosensitivity reaction—Thalidomide—leprosy	0.000379	0.0041	CcSEcCtD
Celecoxib—Weight increased—Thalidomide—leprosy	0.000378	0.00409	CcSEcCtD
Celecoxib—Gastrointestinal pain—Dapsone—leprosy	0.000377	0.00408	CcSEcCtD
Celecoxib—Hyperglycaemia—Thalidomide—leprosy	0.000374	0.00405	CcSEcCtD
Celecoxib—CA4—tendon—leprosy	0.000373	0.0128	CbGeAlD
Celecoxib—Pneumonia—Thalidomide—leprosy	0.000372	0.00403	CcSEcCtD
Celecoxib—Infestation NOS—Thalidomide—leprosy	0.00037	0.00401	CcSEcCtD
Celecoxib—Infestation—Thalidomide—leprosy	0.00037	0.00401	CcSEcCtD
Celecoxib—Stevens-Johnson syndrome—Thalidomide—leprosy	0.000367	0.00397	CcSEcCtD
Celecoxib—Acute coronary syndrome—Thalidomide—leprosy	0.000365	0.00395	CcSEcCtD
Celecoxib—MAPK14—Regulation of toll-like receptor signaling pathway—TLR1—leprosy	0.000364	0.0102	CbGpPWpGaD
Celecoxib—Abdominal pain—Dapsone—leprosy	0.000364	0.00395	CcSEcCtD
Celecoxib—Body temperature increased—Dapsone—leprosy	0.000364	0.00395	CcSEcCtD
Celecoxib—MAPK14—IL12-mediated signaling events—RIPK2—leprosy	0.000364	0.0102	CbGpPWpGaD
Celecoxib—Neuropathy peripheral—Thalidomide—leprosy	0.000363	0.00393	CcSEcCtD
Celecoxib—Myocardial infarction—Thalidomide—leprosy	0.000363	0.00393	CcSEcCtD
Celecoxib—Stomatitis—Thalidomide—leprosy	0.000361	0.0039	CcSEcCtD
Celecoxib—Conjunctivitis—Thalidomide—leprosy	0.00036	0.00389	CcSEcCtD
Celecoxib—Haematuria—Thalidomide—leprosy	0.000353	0.00382	CcSEcCtD
Celecoxib—Epistaxis—Thalidomide—leprosy	0.000349	0.00378	CcSEcCtD
Celecoxib—MAPK14—MAP kinase activation in TLR cascade—NOD2—leprosy	0.000348	0.00973	CbGpPWpGaD
Celecoxib—ALB—testis—leprosy	0.000347	0.0119	CbGeAlD
Celecoxib—Sinusitis—Thalidomide—leprosy	0.000347	0.00376	CcSEcCtD
Celecoxib—Agranulocytosis—Thalidomide—leprosy	0.000345	0.00374	CcSEcCtD
Celecoxib—ABCC4—testis—leprosy	0.000336	0.0115	CbGeAlD
Celecoxib—PDPK1—G beta:gamma signalling through PI3Kgamma—IL2—leprosy	0.000335	0.00935	CbGpPWpGaD
Celecoxib—Rhinitis—Thalidomide—leprosy	0.000333	0.0036	CcSEcCtD
Celecoxib—Hepatitis—Thalidomide—leprosy	0.000332	0.0036	CcSEcCtD
Celecoxib—Hypoaesthesia—Thalidomide—leprosy	0.00033	0.00358	CcSEcCtD
Celecoxib—ABCC4—nervous system—leprosy	0.00033	0.0113	CbGeAlD
Celecoxib—PDPK1—CXCR4-mediated signaling events—HLA-DRB1—leprosy	0.00033	0.00921	CbGpPWpGaD
Celecoxib—Pharyngitis—Thalidomide—leprosy	0.00033	0.00357	CcSEcCtD
Celecoxib—PDPK1—GPVI-mediated activation cascade—IL2—leprosy	0.000329	0.0092	CbGpPWpGaD
Celecoxib—Urinary tract disorder—Thalidomide—leprosy	0.000328	0.00355	CcSEcCtD
Celecoxib—Oedema peripheral—Thalidomide—leprosy	0.000327	0.00354	CcSEcCtD
Celecoxib—Urethral disorder—Thalidomide—leprosy	0.000326	0.00352	CcSEcCtD
Celecoxib—PDPK1—G-protein beta:gamma signalling—IL2—leprosy	0.000319	0.00891	CbGpPWpGaD
Celecoxib—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—leprosy	0.000318	0.00889	CbGpPWpGaD
Celecoxib—Erythema multiforme—Thalidomide—leprosy	0.000314	0.0034	CcSEcCtD
Celecoxib—Eye disorder—Thalidomide—leprosy	0.00031	0.00336	CcSEcCtD
Celecoxib—Tinnitus—Thalidomide—leprosy	0.00031	0.00335	CcSEcCtD
Celecoxib—CA2—tendon—leprosy	0.00031	0.0106	CbGeAlD
Celecoxib—CA4—testis—leprosy	0.000309	0.0106	CbGeAlD
Celecoxib—PDPK1—TCR signaling—CD4—leprosy	0.000309	0.00862	CbGpPWpGaD
Celecoxib—Cardiac disorder—Thalidomide—leprosy	0.000308	0.00334	CcSEcCtD
Celecoxib—MAPK14—TRAF6 Mediated Induction of proinflammatory cytokines—RIPK2—leprosy	0.000304	0.00849	CbGpPWpGaD
Celecoxib—CA4—nervous system—leprosy	0.000303	0.0104	CbGeAlD
Celecoxib—Angiopathy—Thalidomide—leprosy	0.000301	0.00326	CcSEcCtD
Celecoxib—PTGS2—skin of body—leprosy	0.0003	0.0103	CbGeAlD
Celecoxib—Immune system disorder—Thalidomide—leprosy	0.0003	0.00325	CcSEcCtD
Celecoxib—Mediastinal disorder—Thalidomide—leprosy	0.000299	0.00324	CcSEcCtD
Celecoxib—Arrhythmia—Thalidomide—leprosy	0.000297	0.00321	CcSEcCtD
Celecoxib—Alopecia—Thalidomide—leprosy	0.000293	0.00318	CcSEcCtD
Celecoxib—Vomiting—Dapsone—leprosy	0.000293	0.00317	CcSEcCtD
Celecoxib—Mental disorder—Thalidomide—leprosy	0.000291	0.00315	CcSEcCtD
Celecoxib—Headache—Dapsone—leprosy	0.000289	0.00313	CcSEcCtD
Celecoxib—MAPK14—Regulation of toll-like receptor signaling pathway—CYLD—leprosy	0.000288	0.00804	CbGpPWpGaD
Celecoxib—Flatulence—Thalidomide—leprosy	0.000285	0.00308	CcSEcCtD
Celecoxib—Tension—Thalidomide—leprosy	0.000284	0.00307	CcSEcCtD
Celecoxib—Dysgeusia—Thalidomide—leprosy	0.000283	0.00307	CcSEcCtD
Celecoxib—PDPK1—TCR signaling in naïve CD4+ T cells—CD4—leprosy	0.000282	0.00788	CbGpPWpGaD
Celecoxib—Nervousness—Thalidomide—leprosy	0.000281	0.00304	CcSEcCtD
Celecoxib—Back pain—Thalidomide—leprosy	0.00028	0.00303	CcSEcCtD
Celecoxib—Muscle spasms—Thalidomide—leprosy	0.000278	0.00301	CcSEcCtD
Celecoxib—MAPK14—TRAF6 Mediated Induction of proinflammatory cytokines—NOD2—leprosy	0.000276	0.0077	CbGpPWpGaD
Celecoxib—MAPK14—IL12-mediated signaling events—CD8A—leprosy	0.000276	0.00769	CbGpPWpGaD
Celecoxib—PDPK1—Costimulation by the CD28 family—CD4—leprosy	0.000276	0.00769	CbGpPWpGaD
Celecoxib—MAPK14—MyD88 cascade initiated on plasma membrane—RIPK2—leprosy	0.000275	0.00768	CbGpPWpGaD
Celecoxib—Nausea—Dapsone—leprosy	0.000274	0.00296	CcSEcCtD
Celecoxib—MAPK14—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—RIPK2—leprosy	0.000273	0.00761	CbGpPWpGaD
Celecoxib—Vision blurred—Thalidomide—leprosy	0.000272	0.00295	CcSEcCtD
Celecoxib—MAPK14—IL4-mediated signaling events—IL10—leprosy	0.000271	0.00758	CbGpPWpGaD
Celecoxib—MAPK14—IL4-mediated signaling events—CD40LG—leprosy	0.000271	0.00758	CbGpPWpGaD
Celecoxib—MAPK14—MyD88 dependent cascade initiated on endosome—RIPK2—leprosy	0.000268	0.00747	CbGpPWpGaD
Celecoxib—Anaemia—Thalidomide—leprosy	0.000267	0.00289	CcSEcCtD
Celecoxib—Angioedema—Thalidomide—leprosy	0.000264	0.00286	CcSEcCtD
Celecoxib—MAPK14—TCR Signaling Pathway—RIPK2—leprosy	0.000263	0.00734	CbGpPWpGaD
Celecoxib—Vertigo—Thalidomide—leprosy	0.00026	0.00281	CcSEcCtD
Celecoxib—Syncope—Thalidomide—leprosy	0.000259	0.00281	CcSEcCtD
Celecoxib—Leukopenia—Thalidomide—leprosy	0.000259	0.0028	CcSEcCtD
Celecoxib—MAPK14—Toll Like Receptor 9 (TLR9) Cascade—RIPK2—leprosy	0.000258	0.00721	CbGpPWpGaD
Celecoxib—CA2—testis—leprosy	0.000256	0.00876	CbGeAlD
Celecoxib—Palpitations—Thalidomide—leprosy	0.000255	0.00277	CcSEcCtD
Celecoxib—Loss of consciousness—Thalidomide—leprosy	0.000254	0.00275	CcSEcCtD
Celecoxib—MAPK14—MyD88:Mal cascade initiated on plasma membrane—RIPK2—leprosy	0.000254	0.00709	CbGpPWpGaD
Celecoxib—MAPK14—MyD88:Mal cascade initiated on plasma membrane—TLR2—leprosy	0.000254	0.00709	CbGpPWpGaD
Celecoxib—Cough—Thalidomide—leprosy	0.000252	0.00273	CcSEcCtD
Celecoxib—CA2—nervous system—leprosy	0.000252	0.0086	CbGeAlD
Celecoxib—Hypertension—Thalidomide—leprosy	0.00025	0.0027	CcSEcCtD
Celecoxib—MAPK14—MyD88 cascade initiated on plasma membrane—NOD2—leprosy	0.000249	0.00697	CbGpPWpGaD
Celecoxib—MAPK14—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NOD2—leprosy	0.000247	0.0069	CbGpPWpGaD
Celecoxib—Myalgia—Thalidomide—leprosy	0.000246	0.00266	CcSEcCtD
Celecoxib—Arthralgia—Thalidomide—leprosy	0.000246	0.00266	CcSEcCtD
Celecoxib—Chest pain—Thalidomide—leprosy	0.000246	0.00266	CcSEcCtD
Celecoxib—Anxiety—Thalidomide—leprosy	0.000245	0.00266	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Thalidomide—leprosy	0.000244	0.00265	CcSEcCtD
Celecoxib—MAPK14—MyD88-independent cascade—RIPK2—leprosy	0.000244	0.0068	CbGpPWpGaD
Celecoxib—MAPK14—MyD88 dependent cascade initiated on endosome—NOD2—leprosy	0.000243	0.00677	CbGpPWpGaD
Celecoxib—Dry mouth—Thalidomide—leprosy	0.000241	0.00261	CcSEcCtD
Celecoxib—Confusional state—Thalidomide—leprosy	0.000238	0.00258	CcSEcCtD
Celecoxib—MAPK14—Toll-like Receptor Signaling Pathway—TLR2—leprosy	0.000238	0.00664	CbGpPWpGaD
Celecoxib—Oedema—Thalidomide—leprosy	0.000236	0.00255	CcSEcCtD
Celecoxib—Infection—Thalidomide—leprosy	0.000234	0.00254	CcSEcCtD
Celecoxib—MAPK14—Toll Like Receptor 9 (TLR9) Cascade—NOD2—leprosy	0.000234	0.00654	CbGpPWpGaD
Celecoxib—PDPK1—CXCR4-mediated signaling events—CD4—leprosy	0.000233	0.0065	CbGpPWpGaD
Celecoxib—Shock—Thalidomide—leprosy	0.000232	0.00251	CcSEcCtD
Celecoxib—Nervous system disorder—Thalidomide—leprosy	0.000231	0.00251	CcSEcCtD
Celecoxib—Thrombocytopenia—Thalidomide—leprosy	0.000231	0.0025	CcSEcCtD
Celecoxib—Tachycardia—Thalidomide—leprosy	0.00023	0.00249	CcSEcCtD
Celecoxib—MAPK14—MyD88:Mal cascade initiated on plasma membrane—NOD2—leprosy	0.00023	0.00643	CbGpPWpGaD
Celecoxib—Skin disorder—Thalidomide—leprosy	0.000229	0.00248	CcSEcCtD
Celecoxib—PTGS2—tendon—leprosy	0.000229	0.00781	CbGeAlD
Celecoxib—Hyperhidrosis—Thalidomide—leprosy	0.000228	0.00247	CcSEcCtD
Celecoxib—Anorexia—Thalidomide—leprosy	0.000225	0.00244	CcSEcCtD
Celecoxib—MAPK14—IL12-mediated signaling events—HLA-DRB1—leprosy	0.000224	0.00626	CbGpPWpGaD
Celecoxib—MAPK14—MyD88-independent cascade—NOD2—leprosy	0.000221	0.00617	CbGpPWpGaD
Celecoxib—PDPK1—TCR Signaling Pathway—CD4—leprosy	0.00022	0.00615	CbGpPWpGaD
Celecoxib—MAPK14—Activated TLR4 signalling—RIPK2—leprosy	0.000219	0.00612	CbGpPWpGaD
Celecoxib—MAPK14—Activated TLR4 signalling—TLR2—leprosy	0.000219	0.00612	CbGpPWpGaD
Celecoxib—PDPK1—Cardiac Hypertrophic Response—TNF—leprosy	0.000219	0.00611	CbGpPWpGaD
Celecoxib—Musculoskeletal discomfort—Thalidomide—leprosy	0.000215	0.00233	CcSEcCtD
Celecoxib—Insomnia—Thalidomide—leprosy	0.000213	0.00231	CcSEcCtD
Celecoxib—Paraesthesia—Thalidomide—leprosy	0.000212	0.00229	CcSEcCtD
Celecoxib—Dyspnoea—Thalidomide—leprosy	0.00021	0.00228	CcSEcCtD
Celecoxib—Somnolence—Thalidomide—leprosy	0.00021	0.00227	CcSEcCtD
Celecoxib—Dyspepsia—Thalidomide—leprosy	0.000208	0.00225	CcSEcCtD
Celecoxib—MAPK14—Toll Like Receptor 4 (TLR4) Cascade—RIPK2—leprosy	0.000206	0.00575	CbGpPWpGaD
Celecoxib—MAPK14—Toll Like Receptor 4 (TLR4) Cascade—TLR2—leprosy	0.000206	0.00575	CbGpPWpGaD
Celecoxib—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—leprosy	0.000206	0.00575	CbGpPWpGaD
Celecoxib—Decreased appetite—Thalidomide—leprosy	0.000205	0.00222	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Thalidomide—leprosy	0.000204	0.00221	CcSEcCtD
Celecoxib—Fatigue—Thalidomide—leprosy	0.000203	0.0022	CcSEcCtD
Celecoxib—Constipation—Thalidomide—leprosy	0.000202	0.00218	CcSEcCtD
Celecoxib—PDPK1—Signaling by NGF—RIPK2—leprosy	0.000201	0.0056	CbGpPWpGaD
Celecoxib—MAPK14—TCR Signaling Pathway—CD8A—leprosy	0.000199	0.00556	CbGpPWpGaD
Celecoxib—MAPK14—Activated TLR4 signalling—NOD2—leprosy	0.000199	0.00555	CbGpPWpGaD
Celecoxib—Feeling abnormal—Thalidomide—leprosy	0.000194	0.00211	CcSEcCtD
Celecoxib—Gastrointestinal pain—Thalidomide—leprosy	0.000193	0.00209	CcSEcCtD
Celecoxib—Urticaria—Thalidomide—leprosy	0.000187	0.00203	CcSEcCtD
Celecoxib—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—leprosy	0.000187	0.00523	CbGpPWpGaD
Celecoxib—MAPK14—Toll Like Receptor 4 (TLR4) Cascade—NOD2—leprosy	0.000187	0.00522	CbGpPWpGaD
Celecoxib—Body temperature increased—Thalidomide—leprosy	0.000187	0.00202	CcSEcCtD
Celecoxib—Abdominal pain—Thalidomide—leprosy	0.000187	0.00202	CcSEcCtD
Celecoxib—PTGS2—nervous system—leprosy	0.000186	0.00635	CbGeAlD
Celecoxib—MAPK14—Regulation of toll-like receptor signaling pathway—TLR2—leprosy	0.000186	0.00518	CbGpPWpGaD
Celecoxib—MAPK14—Toll-Like Receptors Cascades—TLR2—leprosy	0.000184	0.00512	CbGpPWpGaD
Celecoxib—MAPK14—Toll-Like Receptors Cascades—RIPK2—leprosy	0.000184	0.00512	CbGpPWpGaD
Celecoxib—MAPK14—IL2-mediated signaling events—IFNG—leprosy	0.000178	0.00498	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—CYLD—leprosy	0.000178	0.00496	CbGpPWpGaD
Celecoxib—MAPK14—Monoamine Transport—TNF—leprosy	0.000175	0.0049	CbGpPWpGaD
Celecoxib—Hypersensitivity—Thalidomide—leprosy	0.000174	0.00188	CcSEcCtD
Celecoxib—PTGS2—Overview of nanoparticle effects—TNF—leprosy	0.00017	0.00475	CbGpPWpGaD
Celecoxib—Asthenia—Thalidomide—leprosy	0.000169	0.00183	CcSEcCtD
Celecoxib—Pruritus—Thalidomide—leprosy	0.000167	0.00181	CcSEcCtD
Celecoxib—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—leprosy	0.000166	0.00465	CbGpPWpGaD
Celecoxib—MAPK14—Toll-Like Receptors Cascades—NOD2—leprosy	0.000166	0.00465	CbGpPWpGaD
Celecoxib—MAPK14—ATF-2 transcription factor network—IFNG—leprosy	0.000166	0.00464	CbGpPWpGaD
Celecoxib—MAPK14—IL12-mediated signaling events—IFNG—leprosy	0.000164	0.00458	CbGpPWpGaD
Celecoxib—CYP2D6—testis—leprosy	0.000163	0.00556	CbGeAlD
Celecoxib—CYP3A4—nervous system—leprosy	0.000162	0.00555	CbGeAlD
Celecoxib—Diarrhoea—Thalidomide—leprosy	0.000161	0.00175	CcSEcCtD
Celecoxib—CYP2D6—nervous system—leprosy	0.00016	0.00546	CbGeAlD
Celecoxib—MAPK14—IL2-mediated signaling events—IL2—leprosy	0.000158	0.00442	CbGpPWpGaD
Celecoxib—MAPK14—IL12-mediated signaling events—CD4—leprosy	0.000158	0.00442	CbGpPWpGaD
Celecoxib—Dizziness—Thalidomide—leprosy	0.000156	0.00169	CcSEcCtD
Celecoxib—PDPK1—MicroRNAs in cardiomyocyte hypertrophy—TNF—leprosy	0.000156	0.00435	CbGpPWpGaD
Celecoxib—MAPK14—Amyotrophic lateral sclerosis (ALS)—TNF—leprosy	0.000153	0.00427	CbGpPWpGaD
Celecoxib—PDPK1—Adaptive Immune System—PARK2—leprosy	0.000151	0.00421	CbGpPWpGaD
Celecoxib—Vomiting—Thalidomide—leprosy	0.00015	0.00162	CcSEcCtD
Celecoxib—CA14—Metabolism—SDHD—leprosy	0.000149	0.00416	CbGpPWpGaD
Celecoxib—Rash—Thalidomide—leprosy	0.000149	0.00161	CcSEcCtD
Celecoxib—Dermatitis—Thalidomide—leprosy	0.000149	0.00161	CcSEcCtD
Celecoxib—Headache—Thalidomide—leprosy	0.000148	0.0016	CcSEcCtD
Celecoxib—MAPK14—IL12-mediated signaling events—IL2—leprosy	0.000146	0.00407	CbGpPWpGaD
Celecoxib—CA6—Metabolism—SDHD—leprosy	0.000145	0.00406	CbGpPWpGaD
Celecoxib—CA5A—Metabolism—SDHD—leprosy	0.000145	0.00406	CbGpPWpGaD
Celecoxib—MAPK14—TWEAK Signaling Pathway—TNF—leprosy	0.000141	0.00394	CbGpPWpGaD
Celecoxib—Nausea—Thalidomide—leprosy	0.00014	0.00152	CcSEcCtD
Celecoxib—CA5B—Metabolism—SDHD—leprosy	0.000136	0.00379	CbGpPWpGaD
Celecoxib—MAPK14—Glucocorticoid receptor regulatory network—IFNG—leprosy	0.000128	0.00356	CbGpPWpGaD
Celecoxib—CA12—Metabolism—SDHD—leprosy	0.000126	0.00351	CbGpPWpGaD
Celecoxib—MAPK14—Angiopoietin receptor Tie2-mediated signaling—TNF—leprosy	0.000123	0.00343	CbGpPWpGaD
Celecoxib—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—leprosy	0.000121	0.00338	CbGpPWpGaD
Celecoxib—MAPK14—TCR Signaling Pathway—CD4—leprosy	0.000114	0.00319	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—RIPK2—leprosy	0.000114	0.00319	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—TLR2—leprosy	0.000114	0.00319	CbGpPWpGaD
Celecoxib—MAPK14—Cardiac Hypertrophic Response—TNF—leprosy	0.000114	0.00317	CbGpPWpGaD
Celecoxib—MAPK14—Glucocorticoid receptor regulatory network—IL2—leprosy	0.000113	0.00317	CbGpPWpGaD
Celecoxib—PDPK1—Adaptive Immune System—RIPK2—leprosy	0.00011	0.00307	CbGpPWpGaD
Celecoxib—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—leprosy	0.000108	0.00301	CbGpPWpGaD
Celecoxib—MAPK14—Senescence and Autophagy in Cancer—IFNG—leprosy	0.000105	0.00292	CbGpPWpGaD
Celecoxib—MAPK14—Signaling by NGF—RIPK2—leprosy	0.000104	0.00291	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—NOD2—leprosy	0.000104	0.0029	CbGpPWpGaD
Celecoxib—MAPK14—Corticotropin-releasing hormone—IL2—leprosy	0.000103	0.00289	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—CYLD—leprosy	0.000103	0.00289	CbGpPWpGaD
Celecoxib—CA4—Metabolism—SDHD—leprosy	0.0001	0.0028	CbGpPWpGaD
Celecoxib—PDPK1—Platelet activation, signaling and aggregation—IL2—leprosy	9.87e-05	0.00276	CbGpPWpGaD
Celecoxib—ALB—Vitamin B12 Metabolism—IFNG—leprosy	9.64e-05	0.00269	CbGpPWpGaD
Celecoxib—CA2—Metabolism—SDHD—leprosy	9.61e-05	0.00268	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—CYLD—leprosy	9.23e-05	0.00258	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—PARK2—leprosy	9.14e-05	0.00255	CbGpPWpGaD
Celecoxib—ABCC4—Transmembrane transport of small molecules—SLC11A1—leprosy	8.96e-05	0.0025	CbGpPWpGaD
Celecoxib—PDPK1—Disease—SLC11A1—leprosy	8.44e-05	0.00236	CbGpPWpGaD
Celecoxib—PDPK1—Adaptive Immune System—CD40LG—leprosy	8.42e-05	0.00235	CbGpPWpGaD
Celecoxib—PTGS2—Aryl Hydrocarbon Receptor—TNF—leprosy	8.38e-05	0.00234	CbGpPWpGaD
Celecoxib—PDPK1—Adaptive Immune System—CD8A—leprosy	8.33e-05	0.00232	CbGpPWpGaD
Celecoxib—MAPK14—MicroRNAs in cardiomyocyte hypertrophy—TNF—leprosy	8.1e-05	0.00226	CbGpPWpGaD
Celecoxib—CA9—Metabolism—SDHD—leprosy	8.1e-05	0.00226	CbGpPWpGaD
Celecoxib—ALB—SLC-mediated transmembrane transport—SLC11A1—leprosy	7.98e-05	0.00223	CbGpPWpGaD
Celecoxib—ALB—Folate Metabolism—IFNG—leprosy	7.85e-05	0.00219	CbGpPWpGaD
Celecoxib—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—leprosy	7.84e-05	0.00219	CbGpPWpGaD
Celecoxib—PTGS2—C-MYB transcription factor network—CD4—leprosy	7.72e-05	0.00216	CbGpPWpGaD
Celecoxib—PTGS2—Selenium Micronutrient Network—IFNG—leprosy	7.71e-05	0.00215	CbGpPWpGaD
Celecoxib—ALB—Folate Metabolism—IL2—leprosy	6.97e-05	0.00195	CbGpPWpGaD
Celecoxib—MAPK14—Toll-like Receptor Signaling Pathway—TNF—leprosy	6.94e-05	0.00194	CbGpPWpGaD
Celecoxib—PDPK1—Adaptive Immune System—HLA-DRB1—leprosy	6.78e-05	0.00189	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—TLR2—leprosy	6.66e-05	0.00186	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—RIPK2—leprosy	6.66e-05	0.00186	CbGpPWpGaD
Celecoxib—ALB—Vitamin B12 Metabolism—TNF—leprosy	6.24e-05	0.00174	CbGpPWpGaD
Celecoxib—ALB—Selenium Micronutrient Network—IFNG—leprosy	6.23e-05	0.00174	CbGpPWpGaD
Celecoxib—PTGS2—Spinal Cord Injury—IFNG—leprosy	6.09e-05	0.0017	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—NOD2—leprosy	6.04e-05	0.00169	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—RIPK2—leprosy	5.95e-05	0.00166	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—TLR2—leprosy	5.95e-05	0.00166	CbGpPWpGaD
Celecoxib—ABCC4—Platelet activation, signaling and aggregation—IL2—leprosy	5.86e-05	0.00164	CbGpPWpGaD
Celecoxib—MAPK14—Regulation of toll-like receptor signaling pathway—TNF—leprosy	5.42e-05	0.00151	CbGpPWpGaD
Celecoxib—PTGS2—Spinal Cord Injury—IL2—leprosy	5.41e-05	0.00151	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—NOD2—leprosy	5.39e-05	0.00151	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CYLD—leprosy	5.37e-05	0.0015	CbGpPWpGaD
Celecoxib—MAPK14—Platelet activation, signaling and aggregation—IL2—leprosy	5.13e-05	0.00143	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—CD40LG—leprosy	5.11e-05	0.00143	CbGpPWpGaD
Celecoxib—PDPK1—Hemostasis—IL2—leprosy	5.09e-05	0.00142	CbGpPWpGaD
Celecoxib—ALB—Folate Metabolism—TNF—leprosy	5.08e-05	0.00142	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—CD8A—leprosy	5.05e-05	0.00141	CbGpPWpGaD
Celecoxib—PTGS2—Selenium Micronutrient Network—TNF—leprosy	4.99e-05	0.00139	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—CD4—leprosy	4.98e-05	0.00139	CbGpPWpGaD
Celecoxib—PDPK1—Adaptive Immune System—CD4—leprosy	4.78e-05	0.00134	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—PARK2—leprosy	4.75e-05	0.00133	CbGpPWpGaD
Celecoxib—MAPK14—MAPK Signaling Pathway—TNF—leprosy	4.65e-05	0.0013	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—RIPK2—leprosy	4.31e-05	0.0012	CbGpPWpGaD
Celecoxib—MAPK14—Integrated Pancreatic Cancer Pathway—TNF—leprosy	4.2e-05	0.00117	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—HLA-DRB1—leprosy	4.11e-05	0.00115	CbGpPWpGaD
Celecoxib—ALB—Transmembrane transport of small molecules—SLC11A1—leprosy	4.05e-05	0.00113	CbGpPWpGaD
Celecoxib—ALB—Selenium Micronutrient Network—TNF—leprosy	4.03e-05	0.00113	CbGpPWpGaD
Celecoxib—PTGS2—Spinal Cord Injury—TNF—leprosy	3.94e-05	0.0011	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—RIPK2—leprosy	3.46e-05	0.000967	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—TLR2—leprosy	3.46e-05	0.000967	CbGpPWpGaD
Celecoxib—PDPK1—GPCR downstream signaling—IL2—leprosy	3.22e-05	0.000898	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—NOD2—leprosy	3.14e-05	0.000877	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—SDHD—leprosy	3.12e-05	0.000872	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—IL2—leprosy	3.02e-05	0.000843	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—IFNG—leprosy	3e-05	0.000839	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—IL2—leprosy	2.92e-05	0.000816	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—CD4—leprosy	2.9e-05	0.00081	CbGpPWpGaD
Celecoxib—PTGS2—Disease—SLC11A1—leprosy	2.8e-05	0.000782	CbGpPWpGaD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—leprosy	2.68e-05	0.000749	CbGpPWpGaD
Celecoxib—PDPK1—Disease—CD4—leprosy	2.68e-05	0.000748	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—IL2—leprosy	2.67e-05	0.000745	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CD40LG—leprosy	2.65e-05	0.000741	CbGpPWpGaD
Celecoxib—ALB—Platelet activation, signaling and aggregation—IL2—leprosy	2.65e-05	0.00074	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—IL2—leprosy	2.64e-05	0.000738	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CD8A—leprosy	2.62e-05	0.000733	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—CD4—leprosy	2.59e-05	0.000723	CbGpPWpGaD
Celecoxib—ALB—Metabolism—SDHD—leprosy	2.53e-05	0.000705	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—RIPK2—leprosy	2.24e-05	0.000625	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—HLA-DRB1—leprosy	2.14e-05	0.000597	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—SDHD—leprosy	2.09e-05	0.000582	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—SDHD—leprosy	2.07e-05	0.000577	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—TNF—leprosy	1.96e-05	0.000548	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—IL2—leprosy	1.73e-05	0.000482	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—IFNG—leprosy	1.56e-05	0.000436	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CD4—leprosy	1.51e-05	0.000421	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—IL2—leprosy	1.39e-05	0.000387	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—IL2—leprosy	1.37e-05	0.000382	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—SDHD—leprosy	1.36e-05	0.000381	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—IL2—leprosy	8.97e-06	0.00025	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CD4—leprosy	8.89e-06	0.000248	CbGpPWpGaD
